Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2023-12-08 pm EST			5-day change	1st Jan Change
50.31 ^USD	+0.30%		+0.42%	-30.08%

Dec. 07	Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Dec. 07	Are rate cuts are coming early next year?

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Bristol-Myers Squibb Company

Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...	Dec. 07
Are rate cuts are coming early next year?	Dec. 07
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Dec. 07	MT
S&P, Nasdaq eye higher open on Alphabet boost, payrolls data in focus	Dec. 07	RE
Bristol-Myers Squibb Adds $3 Billion to Buyback Program	Dec. 07	MT
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo and Yervoy Achieved Primary Endpoint	Dec. 07	MT
Bristol Myers: share buyback program expanded	Dec. 07	CF
Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary	Dec. 07	CI
Bristol Myers Adds $3 Billion to Stock Buyback Program	Dec. 07	DJ
Bristol Myers: 5% dividend increase	Dec. 07	CF
Bristol-Myers Squibb Raises Quarterly Dividend to $0.60 a Share from $0.57, Payable on Feb. 1 to Shareholders as of Jan. 5	Dec. 06	MT
Bristol Myers Squibb Raises Dividend 5.3%, to 60 Cents	Dec. 06	DJ
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on February 1, 2024	Dec. 06	CI
UniCredit seeks new chair candidate by early 2024, sources say	Dec. 06	RE
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Diseases	Dec. 06	CI
UniCredit seeks new chair candidate by early 2024, sources say	Dec. 05	RE
Bristol-Myers Squibb Says Application for Bladder Cancer Combo Therapy Gets Priority Review Status From US FDA	Dec. 05	MT
Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer	Dec. 05	DJ
Bristol Myers: priority review status granted for Opdivo	Dec. 05	CF
Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo	Dec. 05	CI
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing	Dec. 01	MT
US FDA investigating safety risk of CAR-T cancer therapies	Nov. 28	RE
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells	Nov. 28	DJ

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Sector

Pharmaceuticals

Calendar

2023-12-10 - American Society of Hematology Meeting - Oral Presentation #667

More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

50.31USD

Average target price

64.13USD

Spread / Average Target

+27.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-30.08%	102 B $
ELI LILLY AND COMPANY	+63.47%	538 B $
NOVO NORDISK A/S	+42.56%	430 B $
JOHNSON & JOHNSON	-12.58%	372 B $
ABBVIE INC.	-7.63%	264 B $
MERCK & CO., INC.	-6.49%	263 B $
ROCHE HOLDING AG	-12.81%	232 B $
NOVARTIS AG	+1.35%	198 B $
ASTRAZENECA PLC	-9.77%	197 B $
PFIZER, INC.	-43.83%	163 B $

Other Pharmaceuticals